<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866225</url>
  </required_header>
  <id_info>
    <org_study_id>C2541007</org_study_id>
    <nct_id>NCT04866225</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE EXTENT OF EXCRETION, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06865571 USING A 14C-MICROTRACER APPROACH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, open-label, non-randomized, 2-period, fixed-sequence, single-dose&#xD;
      study of PF-06865571 in healthy male participants to characterize the ADME properties of&#xD;
      [14C]PF-06865571 following oral administration; and to evaluate the absolute oral&#xD;
      bioavailability (F) and fraction absorbed (Fa) of PF-06865571 following oral administration&#xD;
      of unlabeled PF-06865571 and IV administration of [14C]PF-06865571.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Actual">August 6, 2021</completion_date>
  <primary_completion_date type="Actual">July 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total recovery of radioactivity in urine, feces and total excreta (urine + feces) as percentage of total radioactive dose administered.</measure>
    <time_frame>Period 1, Pre-dose to maximum Day 21.</time_frame>
    <description>To characterize the extent of excretion of total radioactivity in urine and feces following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount (% of administered dose) of radiolabeled PF-06865571 in plasma.</measure>
    <time_frame>Period 1, Pre-dose to Day 6.</time_frame>
    <description>To determine the amount of radiolabeled PF-06865571 in plasma as the % of the administered dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of metabolites of radiolabeled PF-06865571 (% of administered dose) in plasma.</measure>
    <time_frame>Period 1, Pre-dose to Day 6.</time_frame>
    <description>To determine the amount of metabolites of radiolabeled PF-06865571 in plasma as the % of the administered dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount (% of administered dose) of radiolabeled PF-06865571 in urine.</measure>
    <time_frame>Period 1, Pre-dose to maximum Day 21.</time_frame>
    <description>To determine the amount of radiolabeled PF-06865571 in urine as a % of administered dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of metabolites of radiolabeled PF-06865571 (% of administered dose) in urine.</measure>
    <time_frame>Period 1, Pre-dose to maximum Day 21.</time_frame>
    <description>To determine the amount of metabolites of radiolabeled PF-06865571 in urine as a % of administered dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount (% of administered dose) of radiolabeled PF-06865571 in feces.</measure>
    <time_frame>Period 1, Pre-dose to maximum Day 21.</time_frame>
    <description>To determine the amount of radiolabeled PF-06865571 in feces as a % of administered dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of metabolites of radiolabeled PF-06865571 (% of administered dose) in feces.</measure>
    <time_frame>Period 1, Pre-dose to maximum Day 21.</time_frame>
    <description>To determine the amount of metabolites of radiolabeled PF-06865571 in feces as a % of administered dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast of oral radiolabeled PF-06865571 in plasma</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (Clast) of radiolabeled PF-06865571 following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of oral radiolabeled PF-06865571 in plasma</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Maximum plasma concentration of radiolabeled PF-06865571 following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of oral radiolabeled PF-06865571 in plasma</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Time to Cmax following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of oral radiolabeled PF-06865571 in plasma (if data permit)</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of oral radiolabeled PF-06865571 in plasma (if data permit)</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Terminal elimination half-life following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of radioactivity in plasma</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (Clast) of radioactivity following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of radioactivity in plasma</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Maximum plasma concentration of radioactivity following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of radioactivity PF-06865571 in plasma</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Time to Cmax following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of radioactivity in plasma (if data permit)</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Area under the plasma radioactivity concentration-time profile from time zero extrapolated to infinite time following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of radioactivity in plasma (if data permit)</measure>
    <time_frame>Period 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Terminal elimination half-life following administration of a single oral dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of intravenous radiolabeled PF-06865571 in plasma</measure>
    <time_frame>Period 2: Pre-dose, 0.08, 0.17, 0.25, 0.5, 0.75, 1, 3, 6, 9, 13, 21, 33 and 45 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (Clast) of radiolabeled PF-06865571 following administration of a single intravenous dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of intravenous radiolabeled PF-06865571 in plasma</measure>
    <time_frame>Period 2: Pre-dose, 0.08, 0.17, 0.25, 0.5, 0.75, 1, 3, 6, 9, 13, 21, 33 and 45 hours post-dose</time_frame>
    <description>Maximum plasma concentration of radiolabeled PF-06865571 following administration of a single intravenous dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of intravenous radiolabeled PF-06865571 in plasma</measure>
    <time_frame>Period 2: Pre-dose, 0.08, 0.17, 0.25, 0.5, 0.75, 1, 3, 6, 9, 13, 21, 33 and 45 hours post-dose</time_frame>
    <description>Time to Cmax following administration of a single intravenous dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of intravenous radiolabeled PF-06865571 in plasma (if data permit)</measure>
    <time_frame>Period 2: Pre-dose, 0.08, 0.17, 0.25, 0.5, 0.75, 1, 3, 6, 9, 13, 21, 33 and 45 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time following administration of a single intravenous dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of intravenous radiolabeled PF-06865571 in plasma (if data permit)</measure>
    <time_frame>Period 2: Pre-dose, 0.08, 0.17, 0.25, 0.5, 0.75, 1, 3, 6, 9, 13, 21, 33 and 45 hours post-dose</time_frame>
    <description>Terminal elimination half-life following administration of a single intravenous dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of intravenous radiolabeled PF-06865571 in plasma (if data permit)</measure>
    <time_frame>Period 2: Pre-dose, 0.08, 0.17, 0.25, 0.5, 0.75, 1, 3, 6, 9, 13, 21, 33 and 45 hours post-dose</time_frame>
    <description>Systemic clearance following administration of a single intravenous dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss of intravenous radiolabeled PF-06865571 in plasma (if data permit)</measure>
    <time_frame>Period 2: Pre-dose, 0.08, 0.17, 0.25, 0.5, 0.75, 1, 3, 6, 9, 13, 21, 33 and 45 hours post-dose</time_frame>
    <description>Steady-state volume of distribution following administration of a single intravenous dose of radiolabeled PF-06865571.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute oral bioavailability of PF-06865571</measure>
    <time_frame>Period 2: Pre-dose up to 48 hours post-dose</time_frame>
    <description>Dose-normalized plasma AUCinf (if data permit, otherwise AUClast) following oral unlabeled PF-06865571 compared to IV microtracer PF-06865571 in Period 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of the dose absorbed (Fa) for oral PF-06865571</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
    <description>Total urinary radioactivity following oral administration of radiolabeled PF-06865571 in Period 1 and IV microtracer administration of PF-06865571 in Period 2.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm of healthy male participants administered a single oral dose of [14C]PF-06865571; followed by a single dose of unlabeled PF-06865571, and IV administration of [14C]PF-06865571 three hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral [14C]PF-06865571</intervention_name>
    <description>Oral radiolabeled PF-06865571</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral PF-06865571</intervention_name>
    <description>Oral PF-06865571</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV [14C]PF-06865571</intervention_name>
    <description>IV radiolabeled PF-06865571</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male participants, 18 to 60 years of age, inclusive, at the time of signing the&#xD;
             informed consent document.&#xD;
&#xD;
          -  Male participants who are overtly healthy as determined by medical evaluation&#xD;
             including medical history, physical examination, laboratory tests, and cardiac tests.&#xD;
&#xD;
          -  Participants who are nonsmoking for at least 3 months at the time of signing the&#xD;
             informed consent document.&#xD;
&#xD;
          -  BMI of 17.5 to 30.4 kg/m2, inclusive; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  History of irregular bowel movements including irritable bowel syndrome or frequent&#xD;
             episodes of diarrhea or constipation, defined by less than 1 bowel movement on average&#xD;
             per 2 days, or lactose intolerance.&#xD;
&#xD;
          -  History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV,&#xD;
             HBsAg,or HCVAb. Hepatitis B vaccination is allowed.&#xD;
&#xD;
          -  History of SARS-CoV-2 PCR or antibody (eg, IgG, IgM, etc) positive result would&#xD;
             necessitate accompanying history of asymptomatic state for at least 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs.&#xD;
&#xD;
          -  Previous administration with an unapproved drug within 60 days preceding the first&#xD;
             dose of study intervention used in this study.&#xD;
&#xD;
          -  A positive urine drug test.&#xD;
&#xD;
          -  A positive urine cotinine test.&#xD;
&#xD;
          -  A positive COVID-19 (SARS-CoV-2) PCR test.&#xD;
&#xD;
          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more&#xD;
             within 60 days prior to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C2541007</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADME</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

